FCM Analysis GR in Steroid-Treatment Patients

Flow Cytometric Analysis of Glucocorticoid Receptor Using Monoclonal Antibody and Fluoresceinated Ligand Probes in Glucocorticoid-Resistant and -Sensitive Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00600652

Enrollment

150

Registered

2008-01-25

Start date

2006-12-31

Completion date

Unknown

Last updated

2008-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

glucocorticoid-receptor, flow cytometry, glucocorticoid-resistant, prediction

Brief summary

Monitoring the GR with a GR-MoAb and FITC-Dex probes by FCM would be useful and convenient in determination GR before the steroid treatment in clinical, especially in steroid resistant states, in order to design more efficient clinical treatment protocols.

Detailed description

In order to assess the efficacy of this method, 100 patients with nephrotic syndrome and systemic lupus erythematosus receiving sufficient prednisolone thereafter and 50 age- and sex-matched normal controls will be studied.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of SLE and NS

Exclusion criteria

* Receiving hormone replacement therapy or had received hormone replacement therapy in three months before start of the study * Received drugs or drinks containing alcohol within one month * Having symptom such as infection * Supersensitivity and endocrine disturbance.

Outcome results